



HYPO RESOLVE

EASD

European Association
for the Study of Diabetes

Hypo-RESOLVE consortium @EASD

Tuesday, 3rd October 2023

15:15–16:45 OP 11 Be(a)ware of hypoglycaemia unawareness, Chair: S.R. Heller, UK
(Barcelona Hall)

- 62 HIT4HYPOS CGM analysis: high intensity interval training reduces nocturnal hypoglycaemia in people with type 1 diabetes and impaired awareness of hypoglycaemia; C.M. Farrell, G. Cappon, D. West, A. Facchinetti, R.J. McCrimmon, UK, Italy
- 65 Meta-genome-wide association studies identify potential SNPs and enriched pathways for impaired awareness of hypoglycaemia; M.M. Van der Klauw, R.D. Varkevisser, N. Ali, A. Alaswad, IAH GWAS research group, Dutch Diabetes Pearl Genomics consortium, C.-J. Xu, Y. Li, C.J. Tack, B.H. Wolffenbuttel, B.E. De Galan, Netherlands, Germany
- 66 Reduced defensive responses to hypoglycaemia are associated with a loss of neuronal activation in the dorsomedial hypothalamus in mice; L. Sheppard, E. Staricoff, E. Naden, M. Josipovic, C. Riches, B. De Galan, B. Thorens, U. Pedersen-Bjergaard, A. McNeilly, R. McCrimmon, M. Evans, UK, Netherlands, Switzerland, Denmark

16:30–18:30 IHSG SYMPOSIUM: Has technology solved the problems around hypoglycaemia?
(Chicago Hall)

- Introduction & Closing remarks; Simon Heller, UK
- Using technology to assess risk; Julia Mader, Austria
- Psychoeducational solutions amidst the emergence of new technology; Stephanie Amiel, UK

HYPO RESOLVE

EASD

European Association
for the Study of Diabetes

Hypo-RESOLVE consortium @EASD

Wednesday, 4th October 2023

09:00–10:30 Hypo-RESOLVE Symposium (Lima Hall)

- Introduction to the project and hypoglycaemia in CVD; Bastiaan E de Galan (Chair), Netherlands
- Clinical and psychological relevance of sensor-detected low glucose: the Hypo-METRICS study; Pratik Choudhary, UK
- Health-economic impact of hypoglycaemia; Jill Carlton, UK
- The classification of hypoglycaemia: then and now; Simon R Heller, UK
- Commentary; Brian Frier, UK

12:45–13:45 SO 69 “When I’m sixty-four” (low and not-so-young)

- 831 The Hypo-RESOLVE QoL: a new patient reported outcome (PRO) to quantify the impact of hypoglycaemia on health-related quality of life; J. Carlton, P. Powell, D. Rowen, M. Broadley, F. Pouwer, J. Speight, S. Heller, M.-A. Gall, M. Rosilio, C.J. Child, J. Comins, R.J. McCrimmon, B. De Galan, Hypo-RESOLVE Consortium, UK, Denmark, Australia, France, Netherlands
- 836 Distinct inflammatory functions of murine BMDMs following exposure to acute vs recurrent hypoglycaemia; J. Kerr, A.D. McNeilly, C. Forteach, J. Deyell, K. Smellie, R. Hall, R. Stienstra, B.D. Galan, M. Evans, U. Pedersen-Bjergaard, B. Thorens, R.J. McCrimmon, UK, Netherlands, Denmark, Switzerland

14:00–15:00 SO Quantifying hypoglycaemia: from mild to mad

- 793 Factors associated with symptomatic hypoglycaemia are different from those for CGM hypoglycaemia in people living with type 1 diabetes: the Hypo-METRICS study; P. Divilly, Z. Mahmoudi, G. Martine-Edith, N. Zaremba, B. De Galan, U. Pedersen-Bjergaard, R. McCrimmon, E. Renard, S. Heller, M. Evans, J. Mader, J. Speight, S. Amiel, F. Pouwer, P. Choudhary, UK, Netherlands, Denmark, France, Austria, Australia
- 794 How well does sensor-detected hypoglycaemia from short-duration CGM reflect person-reported hypoglycaemia?; P.M. Baumann, M. Cigler, D. Kuznetsov, M. Rosilio, D. Hochfellner, M. Ibberson, S.A. Amiel, S. Heller, M.-A. Gall, B. De Galan, T.R. Pieber, P. Choudhary, J.K. Mader, Hypo-RESOLVE Consortium, Austria, Switzerland, France, UK, Denmark, Netherlands
- 795 Recurrent hypoglycaemia induces pro-inflammatory priming of BMDMs and promotes vascular dysfunction in a mouse model of type 2 diabetes and CVD; C. Forteach, A.D. McNeilly, J. Kerr, J. Deyell, J. Gallagher, A. Iqbal, M.F. Arshad, R. Stienstra, M.L. Evans, B. Thorens, U. Pederson-Bjergaard, B.E. De Galan, R.J. McCrimmon, Hypo-RESOLVE Consortium, UK, Netherlands, Switzerland, Denmark
- 796 Metabolic adaptations of a hypothalamic neuronal cell line, mHypoA-2/21, in response to recurrent hypoglycaemia; H.J. Merchant, M.J. Ashford, R.J. McCrimmon, A.D. McNeilly, UK
- 798 Quantifying intensity of hypoglycaemia symptoms by diabetes type and hypoglycaemia awareness status: results from the Hypo-METRICS study; G. Martine-Edith, P. Divilly, N. Zaremba, U. Søholm, M. Broadley, P. Baumann, B. De Galan, R.J. McCrimmon, M. Evans, J.K. Mader, S.A. Amiel, J. Speight, F. Pouwer, P. Choudhary, for the Hypo-RESOLVE Consortium, UK, Denmark, Austria, Netherlands, Australia

HYPO RESOLVE

EASD

European Association
for the Study of Diabetes

Hypo-RESOLVE consortium @EASD

Friday, 6th October 202

10:30–11:30 OP 46 Endothelium and diabetes complications (Barcelona Hall)

- 265 Activation of the Nrf2 pathway offers microvascular protection against recurrent hypoglycaemia in type 1 diabetes; A.D. McNeilly, C. Forteach, J.R. Gallagher, H.J. Merchant, A.T. Dinkova-Kostova, F. Khan, M.L. Evans, B. Thorens, U. Pederson-Bjergaard, B.E. De Galan, R.J. McCrimmon, UK, Switzerland, Denmark, Netherlands

13:30–15:00 Brain control of islet function (Lima Hall)

- Central deficiency of IL-6Ra in mice impairs glucose-stimulated insulin secretion; Rory J McCrimmon, UK

www.hypo-resolve.eu



The HypoResolve project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), and The Leona M. and Harry B. Helmsley Charitable Trust.